ADC Therapeutics Cuts 17% Workforce to Save $10M, Targets Q4 sBLA
ADCT•ADC Therapeutics will cut 17% of its global workforce, generating approximately $10 million in annual savings and incurring $3 million in one-time severance charges in Q2. The company now plans a pre-sBLA FDA meeting in August 2026, full sBLA submission in Q4 2026, and LOTIS-7 data by year-end 2026.
1. Strategic Reorganization and Cost Savings
ADC Therapeutics is reducing its global headcount by approximately 17%, driven by the planned completion of LOTIS-5 and LOTIS-7 trials and operational efficiencies. The reorganization is expected to deliver about $10 million in annualized savings and incur roughly $3 million in one-time pre-tax charges for severance and related costs, mostly recognized in Q2 2026.
2. Upcoming Regulatory Milestones
The company has scheduled a pre-supplemental BLA meeting with the FDA in August 2026 to discuss ZYNLONTA combined with rituximab for relapsed or refractory DLBCL. Following this, ADC Therapeutics plans to submit the full sBLA in the fourth quarter of 2026.
3. Clinical Trial Progress and Outlook
ADC Therapeutics continues to advance the LOTIS-7 Phase 1b trial evaluating ZYNLONTA with glofitamab in second-line and later DLBCL, with top-line data expected by the end of 2026. The company also supports multiple investigator-initiated trials exploring ZYNLONTA in indolent lymphomas.
